Patents Examined by Raymond J. Henley
  • Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
    Patent number: 11154553
    Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: October 26, 2021
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Arash Raoufinia
  • Methods of treatment
    Patent number: 11154545
    Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: October 26, 2021
    Assignee: BOW RIVER LLC
    Inventors: Sundar Srinivasan, Christina Chow
  • Use of cannabinoids in the treatment of epilepsy
    Patent number: 11154517
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: October 26, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Substituted oxadiazole chemical compound and composition containing said chemical compound and use thereof
    Patent number: 11147802
    Abstract: Provided are a substituted oxadiazole chemical compound and composition containing said chemical compound and use thereof; said substituted oxadiazole chemical compound is the oxadiazole chemical compound as represented by formula (I), or its crystalline form, pharmaceutically acceptable salt, prodrug, stereoisomer, hydrate, or solvent compound. The disclosed substituted oxadiazole chemical compound and composition containing said chemical compound are capable of inhibiting indoleamine 2,3-dioxygenase; it also has better pharmacokinetic parameter attributes and is capable of improving the drug concentration of the chemical compound in an animal body, thus improving the therapeutic efficacy and safety of the drug.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: October 19, 2021
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Huanyin Li
  • Method of decreasing the fluctuation index of dextromethorphan
    Patent number: 11147808
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: October 19, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for treating diseases associated with uncontrolled inflammatory responses
    Patent number: 11147815
    Abstract: Methods of treating, controlling or managing diseases associated with uncontrolled inflammatory responses are provided. These methods comprise the administration of small molecule compounds that alter the activity of Tripartite motif containing 8 (TRIM8) in blood monocytes. Also provided are pharmaceutical compositions that comprise small molecule compounds that specifically target the E2-RING domain or the RING-RING dimerization domain of TRIM8 for the treatment, control or management of diseases associated with uncontrolled inflammatory responses.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: October 19, 2021
    Inventors: Jason Barbour, David Ott
  • EZH2 inhibitors for treating cancer
    Patent number: 11147819
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: October 19, 2021
    Assignee: Epizyme, Inc.
    Inventors: Scott Ribich, Michael Thomenius
  • Modified free amino acid formulation and uses
    Patent number: 11147785
    Abstract: A composition and methods of administration are provides utilizing Monosodium L-Glutamate Monohydrate in a stabilized form at an alkaline pH.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: October 19, 2021
    Inventors: Jack Mentkow, Lisa Mentkow
  • Methods for predicting and determining responsiveness to activators of JNK kinase
    Patent number: 11137400
    Abstract: The present disclosure relates to methods for predicting and/or determining responsiveness to an activator of JNK kinase activity. The present disclosure further relates to improved methods for treating a cancer patient with an activator of JNK kinase activity. The present disclosure also relates to methods for screening for a modulator of XBP1s protein phosphorylation.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: October 5, 2021
    Assignee: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventor: Hongjiao Ouyang
  • Devices for the administration of pharmaceutical suspensions
    Patent number: 11135191
    Abstract: The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: October 5, 2021
    Assignee: SynAgile Corporation
    Inventors: Adam Heller, Ephraim Heller, John Spiridigliozzi, Steven Diianni, Evangelos C. Eleftheriou
  • Dosage regimen of an S1P receptor modulator
    Patent number: 11135197
    Abstract: The present application relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disease or disorder, for example multiple sclerosis (MS).
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: October 5, 2021
    Assignee: Argentum Pharmaceuticals LLC
    Inventor: Jeffrey R. Gardner
  • Methods of sensitizing estrogen receptor positive (ER+) breast cancer cells to endocrine therapy
    Patent number: 11135224
    Abstract: Aspects of the technology are directed to a method of increasing sensitivity of estrogen receptor positive (ER+) breast cancer cells to treatment with an endocrine therapy. The method involves selecting ER+ breast cancer cells, and administering to the selected cells (i) one or more mammalian target of rapamycin (mTOR) inhibitors and (ii) one or more MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1) inhibitors in an effective amount to increase the sensitivity of the ER+ breast cancer cells to treatment with the endocrine therapy. Methods of treating a subject having ER+ breast cancer are also disclosed.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: October 5, 2021
    Assignee: NEW YORK UNIVERSITY
    Inventors: Robert J. Schneider, Phillip A. Geter, Sofia Bakogianni
  • Amino-triazolopyridine compounds and their use in treating cancer
    Patent number: 11136340
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: October 5, 2021
    Assignee: AstraZeneca AB
    Inventors: Maurice Raymond Verschoyle Finlay, Frederick Woolf Goldberg, Attilla Kuan Tsuei Ting
  • Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
    Patent number: 11125760
    Abstract: Disclosed herein are methods for diagnosing a subject with loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia. Also disclosed herein are methods and compositions for treating a subject for loss and/or distortion of taste or smell, e.g., hyposmia, dysosmia, anosmia, phantosmia, hypogeusia, dysgeusia, phantogeusia, and/or ageusia.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: September 21, 2021
    Assignee: Cyrano Therapeutics, Inc.
    Inventor: Robert I. Henkin
  • Dantrolene and analogs thereof for the chronic treatment and prevention of dyssynchronous cardiac dysfunction
    Patent number: 11123328
    Abstract: The present disclosure relates to methods for the chronic treatment of dyssynchronous cardiac dysfunction (including non-arrhythmia cardiac dysfunction such as heart failure, cardiomyopathy, viral myocarditis, ischemia induced cardiomyopathy, ischemia, chemotherapy, pacing induced cardiomyopathy or ion channel mutation related dysfunction) and for the prevention or treatment of diseases or conditions associated with dyssynchronous cardiac dysfunction. The method comprises chronically administering to a patient an effective amount of dantrolene, or derivative or analogs thereof (such as azumolene).
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: September 21, 2021
    Assignee: University Health Network
    Inventor: Kumaraswamy Nanthakumar
  • Methods of treating disorders associated with glycosylation defective proteins
    Patent number: 11110076
    Abstract: A method of treating a glycosylation-defective protein associated disease or disorder in a subject, the method includes administering to the subject a therapeutically effective amount of a Sarco/ER ATPase (SERCA) inhibitor.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: September 7, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Alagramam N. Kumar, Suhasini Gopal Ramanujam
  • Methods of treating disorders using CSF1R inhibitors
    Patent number: 11103507
    Abstract: Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: August 31, 2021
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
  • JAK1 pathway inhibitors for the treatment of cytokine-related disorders
    Patent number: 11103510
    Abstract: This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: August 31, 2021
    Assignee: Incyte Corporation
    Inventors: Michael O'Neill Montgomery, Ahmad Naim, Susan Snodgrass
  • Crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
    Patent number: 11103512
    Abstract: A crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be prepared as a pharmaceutical composition.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: August 31, 2021
    Assignee: Merck Patent GmbH
    Inventors: Michael Lange, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuning, Marco Poma, Edoardo Burini
  • Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection
    Patent number: 11096940
    Abstract: Provided herein are methods for treating and/or preventing hepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV) infection in a patient, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt or tautomer thereof (collectively referred to herein as “Compound 1”) to the patient having HCC characterized by HBV infection.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: August 24, 2021
    Assignee: Celgene Corporation
    Inventors: Ellen Filvaroff, Kristen M. Hege, Shaoyi Li